| 201/450 | US=15 / Gastro Philip PA, Heilbrun LK, Abrams J. Pitfalls in clinical trial and future directions. In: Lowy AM, Leach SD, Philip PA. Pancreatic cancer. New York: Springer, 2008. p. 723-31. ISBN 978-0-387-69250-0. |
| 203/450 | US=17 / Pelvis Folpe AL, Gown AM. Immunohistochemistry for analysis of soft tissue tumors. In: Weiss SW, Goldblum JR. Enzinger and Weiss's soft tissue tumors. 5th ed. Philadelphia: Elsevier Mosby, 2008. p. 129-74. ISBN 978-0-323-04628-2. IMUNOHISTOQUIMICA; TUMORES EM TECIDOS MOLES; FILAMENTOS INTERMEDIARIOS; VIMENTINA; CITOQUERATINAS; ANTIGENO DE MEMBRANA EPITELIAL; MARCADORES DE DIFERENCIACAO MUSCULAR; DESMINA; ACTINA; FATORES DE TRANSCRICAO MIOGENICOS; MARCADORES DA BAINHA DOS NERVOS; MARCADORES NEUROECTODERMAL; MARCADORES DE MELANOCITICOS; MARCADORES DE ENDOTELIO; MESOTELIOMA; CARCINOMA; MARCADORES DE TUMORES GASTROINTESTINAIS ESTROMAIS; MARCADORES PROGNOSTICOS |
| 204/450 | US=18 / Gastro Shin EJ, Canto MI. The clinical assessment of pancreatic cancer. In: Beger HG, Matsuno S, Cameron JL. Diseases of the pancreas: current surgical therapy. New York: Springer, 2008. p. 527-40. ISBN 978-3-540-28655-4. CANCER DE PANCREAS; SINTOMAS E SINAIS; MARCADORES TUMORAIS; ULTRASSOM ENDOSCOPICO |
| 205/450 | US=18 / Dermatologia Schwartz RA. Cutaneous markers of internal malignancy. In: ___. Skin cancer: recognition and management. 2nd ed. Massachusetts: Blackwell Science, 2008. p. 283-304. ISBN 978-1-4051-5961-6. MARCADORES CUTANEOS DE MALIGNIDADE INTERNA; SINDROME DE PEUTZ-JEGHERS; SINDROMA DE MUIR-TORRE; NEUROFIBROMATOSE; GLUCAGONOMA SINDROME; FLORIDO CUTANEA PAPILOMATOSE; LESER-TRELAT; ACANTOSE NIGRICANS; DERMATOSE NEUTROFILICA AGUDA; ICTIOSE ADQUIRIDA; HYPPERTRICHOSIS LANAGINOSA ADQUIRIDA |
| 206/450 | US=25 / Urologia Canto EI, Slawin KM. Newly recognized forms of prostate-specific antigen and emerging molecular markers. In: Jones JS. Prostate biopsy: indications, techniques, and complications. New Jersey: Humana Press, 2008. p. 43-59. (Currrent Clinical Urology) ISBN 978-1-58829-790-7. ANTIGENO PROSTATICO ESPECIFICO; EMERGENTES MARCADORES MOLECULARES; ANTIGENO ESPECIFICO DA PROSTATA (PSA); FORMAS MOLECULARES DE PSA LIVRE; RASTREIO DO CANCER DA PROSTATA; MALDI-TOF; SELDI-TOF |
| 207/450 | US=23 / Câncer Lumachi F, Basso SMM, Basso U. Breast cancer recurrence: role of serum tumor markers CEA and CA 15-3. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: breast carcinoma. v.1. New York: Springer, 2008. p. 109-15. ISBN 978-1-4020-8368-6. CANCER DE MAMA; CANCER DE MAMA RECORRENTE; PAPEL DO SORO; MARCADORES TUMORAIS; CEA; CA 15-3; ANTIGENO CARCINOEMBRIONARIO |
| 208/450 | US=23 / Câncer Feng Q, Kiviat NB. Breast cancer patients: diagnostic epigenetic markers in blood. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: breast carcinoma. v.1. New York: Springer, 2008. p. 125-40. ISBN 978-1-4020-8368-6. CANCER DE MAMA. DIAGNOSTICO; MARCADORES EPIGENETICOS NO SANGUE; ANALISE DE METILACAO; METILACAO-ESPECIFICA PCR; METODO DE REACAO EM CADEIA POR POLIMERASE; ANALISE DE DADOS |
| 209/450 | US=23 / Câncer Lin SR, Wang JY, Huang MY, Chen CC. Breast cancer patients: detection of circulating cancer cell-related mRNA markers with membrane array method. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: breast carcinoma. v.1. New York: Springer, 2008. p. 141-55. ISBN 978-1-4020-8368-6. CANCER DE MAMA; DETECCAO DE MARCADORES CIRCULANTES; METODO DE MATRIZ DE MRNA; METODO DE MATRIZ DE MEMBRANA; REACAO DA TRANSCRIPTASE REVERSA |
| 210/450 | US=28 / Biol/Mol Longo R, Torino F, Gasparini G. Prognostic and predictive significance of surrogate biomarkers of angiogenesis. In: Teicher BA, Ellis LM. Antiangiogenic agents in cancer therapy. 2 ed. Houston: Humana Press, 2008. p. 487-508. ISBN 978-1-58829-870-6. |
| 211/450 | US=23 / Câncer Mumenthaler SM, Yoon N, Li A, Mah V, Chang G, Nooraie F, Elshimali Y, Hanna S, Kim S, Horvath S, Apple S, Chia D, Seligson DB, Goodglick L. Tissue microarrays: construction and utilization for biomarker studies. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: breast carcinoma. v.1. New York: Springer, 2008. p. 217-34. ISBN 978-1-4020-8368-6. CANCER DE MAMA; TISSUE MICROARRAYS (TMA); BIOMARCADORES; PROTOCOLOS DE MARCADORES; EXPRESSAO DE BIOMARCADORES; ANALISES DE DADOS; FERRAMENTAS ESTATISTICAS |
| 212/450 | US=23 / Câncer Esposito NN, Dabbs DJ. Phyllodes tumours of the breast: prognostic assessment using immunohistochemistry. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: breast carcinoma. v.1. New York: Springer, 2008. p. 263-73. ISBN 978-1-4020-8368-6. CANCER DE MAMA; TUMOR PHYLLODES; IMUNOHISTOQUIMICA; AVALIACAO PROGNOSTICA; MARCADORES DE PROLIFERACAO CELULAR; GENES SUPRESSORES DE TUMOR; P53; RECEPTORES DE ESTEROIDES; PROTEINAS; FATORES DE CRESCIMENTO EPIDERMICO; HER-2/NEU; ANALISE CROMOSSOMICA; ANALISE MOLECULAR; ANALISE HISTOPATOLOGICA |
| 213/450 | US=35 / Biol/Mol Hennessy B, Bast Junior RC, Gonzalez-Angulo AM, Mills GB. Early detection of cancer: molecular screening. In: Mendelsohn J, Howley PM, Israel MA,Gray JW, Thompson CB. The molecular basis of cancer. 3rd ed. Philadelphia: Saunders Elsevier, 2008. p. 335-47. ISBN 978-1-4160-3703-3. DETECCAO PRECOCE DO CANCER; TRIAGEM MOLECULAR; PRATICA CLINICA; MARCADORES MOLECULARES |
| 214/450 | US=35 / Biol/Mol LoRusso PM, Bekele BN, Boerner SA, Davis DW, Evelhoch JL, Herbst RS. Phase 1 trials today. In: Mendelsohn J, Howley PM, Israel MA,Gray JW, Thompson CB. The molecular basis of cancer. 3rd ed. Philadelphia: Saunders Elsevier, 2008. p. 553-70. ISBN 978-1-4160-3703-3. |
| 215/450 | US=23-A / Câncer Dingli D, Pacheco JM. Successful cancer treatment: eradication of cancer stem cells. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: general methods and overviews, lung carcinoma and prostate carcinoma. v.2. New York: Springer, 2008. p. 179-91. ISBN 978-1-4020-8441-62. CANCER; CELULAS-TRONCO; CANCER. TRATAMENTO; ERRADICACAO DO CANCER; MARCADORES |
| 216/450 | US=23-A / Câncer El-Sharkawy SL, Abbas NF, El-Hefnawy NG. Prognostic markers in prostatic carcinoma. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: general methods and overviews, lung carcinoma and prostate carcinoma. v.2. New York: Springer, 2008. p. 465-79. ISBN 978-1-4020-8441-62. CANCER; CANCER DE PROSTATA; MARCADORES PROGNOSTICOS; CARCINOMA DA PROSTATA |
| 217/450 | US=23-C / Câncer Zlobec I, Lugli A. Prognostic significance of protein markers in colorectal cancer stratified by mismatch repair status. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: colorectal cancer. v.4. New York: Springer, 2008. p. 227-40. ISBN 978-1-4020-9544-3. CANCER COLORRETAL; PROGNOSTICO; MARCADORES DE PROTEINAS; CANCER COLORRETAL ESTRATIFICADA; REPARO MISMATCH; MICROSSERIES DE TECIDO; ANALISE ESTATISTICA; FATORES PROGNOSTICOS; FENOTIPOS MULTIMARKER |
| 218/450 | US=27 / Imagem Davis BJ, Kruse J, Goulet CC, Herman MG. The use of fiducial markers for IGRT in prostate cancer: the mayo clinic approach. In: Valicenti RK, Dicker AP, Jaffray DA. Image-guided radiation therapy of prostate cancer. New York: Informa Helthcare, 2008. p. 85-94. ISBN 978-1-420-06078-2. IMAGEM; CANCER DE PROSTATA; MARCADORES FIDUCIAIS; IGRT; CANCER DE PROSTATA; RADIOTERAPIA GUIADA POR IMAGEM; CONTROLE DE QUALIDADE |
| 219/450 | US=434 / Tese/FAP Duarte AL. Análise da contribuição da pesquisa das mutações nos genes BRAF, HRAS, NRAS, KRAS e PIK3CA em espécimes obtidos por punção aspirativa por agulha fina para avaliação pré-operatória de nódulos tireoidianos. [Analysis of the contribution of the BRAF, HRAS, NRAS, KRAS and PIK3CA mutations in fine needle aspiration biopsy specimens for the preoperative evaluation of thyroid nodules]. São Paulo, 2012. 85 p. Tese(Doutorado)-Fundação Antonio Prudente. Disponível em: http://accamargo.phlnet.com.br/Doutorado/2012/US434/US434.pdf BIOPSIA ASPIRATIVA POR AGULHA FINA; GENES; NODULO DA GLANDULA TIREOIDE; MUTACAO; GLANDULA TIREOIDE |
| 220/450 | US=436 / Tese/FAP Molina GC. Identificação de marcadores moleculares de prognóstico para adenocarcinoma de próstata utilizando abordagem quantitativa baseada em sequências. [Identification of prognostic molecular markers for prostate adenocarcinoma exploiting a quantitative approach based on sequencing]. São Paulo, 2012. 116 p. Tese(Doutorado)-Fundação Antonio Prudente. Disponível em: http://accamargo.phlnet.com.br/Doutorado/2012/GustavoMolina/GustavoMolina.pdf MARCADORES BIOLOGICOS; NEOPLASIAS DA PROSTATA; SEQUENCIAMENTO; EXPRESSAO GENICA; PROGNOSTICO |